Pomalidomide with rituximab and methotrexate for brain lymphoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of three drugs (pomalidomide, rituximab, and methotrexate) for people who have just been diagnosed with a type of lymphoma that started in the brain or spinal cord. The goal is to see if this drug cocktail is safe and effective as a first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma called diffuse large B-cell lymphoma that has a protein called CD20 on its surface.
- The lymphoma must be only in your brain, spinal cord, eyes, or the lining around them – not anywhere else in your body.
- You must not have had chemotherapy or radiation before (except for a very short course of steroids like dexamethasone).
- You are between 18 and 75 years old.
- You must have a tumor that is at least 1 cm across on a special MRI scan.
- You must agree to use effective birth control during treatment and for 6 months after.
- You must not have other active cancers or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (methotrexate, rituximab, sintilimab, and pirtobrutinib) against standard therapy for people with newly diagnosed primary central nervous system lymphoma (PCNSL) that has not been treated before. It aims to see if the combo works better and has manageable side effects.
This trial tests a combination of chemotherapy drugs to treat lymphoma that started in your brain. The goal is to see if this treatment helps without having to use whole-brain radiation.
This trial tests a combination of three drugs (poseltinib, rituximab, and lenalidomide) for people with primary central nervous system lymphoma that has come back or not responded to earlier treatment. The goal is to see if this new mix can help control the disease.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This trial tests three drugs together—pomalidomide, an anti-PD-1 antibody, and selinexor—to treat primary central nervous system lymphoma (a blood cancer in the brain) that has returned after previous treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
This Phase 2 study tests a combination treatment to shrink primary central nervous system lymphoma that starts in the brain, spinal cord, meninges, or eye. It may help patients who have not had anti-cancer treatment yet, but it requires specific cancer type and health conditions.
Hear when a new PCNSL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.